Graham Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting second-quarter and first-half financial results for fiscal year 2027.
Advanced Flower Capital Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 5, 2026, reporting a net increase in net assets from operations of $6,400,248 for the third quarter.
Envoy Medical, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026, disclosing a net loss of $14,265 thousand for the nine months and $3,932 thousand for the …
SAB Biotherapeutics, Inc. (NASDAQ:SABS) filed its quarterly report for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing a net loss of $22.3 million for the third quarter and a cumulative net loss of $63.7 million for the first …
Cronos Group Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the three and nine months ended September 30, 2026, reporting net revenue of $63,450 thousand for the third quarter.
Cronos Group Inc. filed a Form 8-K with the SEC on November 5, 2026, announcing the release of its financial results for the third quarter ended September 30, 2026.
Lucky Strike Entertainment Corporation filed an 8-K on November 5, 2026, announcing preliminary financial results for the first quarter of fiscal year 2027, which ended on September 27, 2026.
Akebia Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.
Lucky Strike Entertainment Corporation filed its Form 10-Q for the quarterly period ended September 27, 2026, with the SEC on November 5, 2026, reporting total revenues of $302.6 million and a net loss of $25.7 million for the quarter.
Cabaletta Bio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing financial and operational information as a late-stage clinical biotechnology company.